Intoduction: Breast cancer is a significant healthcare problem worldwide. Surgery
remains the treatment of choice combined with other modalities such as
chemotherapy, radiation, and immunotherapy such as Artemisia vulgaris (AV).
Selective cytotoxicity of AV is intended as a supplementation to AdriamycinCyclophosphamide, improving the response rate of chemotherapy in
adenocarcinoma mammae. M ethod: This study used a "Post-test only control group
design" on 24 females C3H mice that were randomly selected and divided into four
groups: group K (control), P1 (chemotherapy), P2 (extract), and P3 (combination).
Adenocarcinoma mammae come from the inoculation of donor mice. Chemotherapy
of Adriamycin 60 mg / m2 and Cyclophosphamide 600 mg / m2 were given in two
cycles. AV 13 mg (0.2 ml) was given once daily orally. NF-κB expression and CD34
were evaluated using imunohistochemical staining. Result: The expression of NFκB and microvascular density of CD 34 were obtained in groups of K, P1, P2, P3
Statistical analysis showed significant decrease in the expression of NF-κB between
groups K and P1, P2, P3. Correlation analysis between NF-κB expression with CD
34 was found to have significant correlation (p = 0,039 and r = 0,897). Conclusion:
Artemisia vulgaris can reduce angiogenesis by decreasing NF-κB expression and the
microvascular density CD34 of adenocarcinoma mammae of C3H mice treated with
Adriamycin-Cyclophosphamide chemotherapy and can improve the effectivity.